Nektar Therapeutics Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Nektar Therapeutics (NKTR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$20.66 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2018-03-01
- Nektar Therapeutics effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2017 was -$20.66M, a 4013.83% decline from fiscal 2016.
- Nektar Therapeutics effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2016 was $528.00K, a 21.66% decline from fiscal 2015.
- Nektar Therapeutics effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2015 was $674.00K, a 76.20% decline from fiscal 2014.
- Nektar Therapeutics effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2014 was $2.83M, a 945.02% increase from fiscal 2013.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2017-12-31 | -$20.66M 10-K · filed 2018-03-01 |
| 2016-12-31 | $528.00K 10-K · filed 2018-03-01 |
| 2015-12-31 | $674.00K 10-K · filed 2018-03-01 |
| 2014-12-31 | $2.83M 10-K · filed 2017-03-01 |
| 2013-12-31 | $271.00K 10-K · filed 2016-02-29 |
| 2012-12-31 | $236.00K 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |